By: Melissa Sattley
Magainin Pharmaceuticals Inc. recently announced successful results in phase III trials for FDA approval of Cytolex, their topical antibiotic cream for the treatment of foot ulcers.
After successful results in its first trial studies of Cytolex’s use for treating infected foot ulcers in September 1996, Magainin entered into an agreement with SmithKline Beecham in February 1997 allowing them to develop, supply and market Cytolex in the United States.
“Our two studies represent, to our knowledge, the largest database of clinical information on infected diabetic foot ulcers that has been assembled,” says Jay Moorin, chairman, president and chief executive officer of Magainin.
“If approved for marketing by the FDA, we expect that Cytolex will be the first antibiotic specifically labeled (by the FDA) for the treatment of infection in diabetic foot ulcers and will provide physicians an important alternative to systemic therapy.”